M C53 (Carbidopa and levodopa (orally disintegrating) 25 mg / 250 mg)

Pill imprint M C53 has been identified as Carbidopa and levodopa (orally disintegrating) 25 mg / 250 mg.

Carbidopa/levodopa is used in the treatment of parkinson's disease; restless legs syndrome; neuroleptic malignant syndrome; gtp-ch deficiency and belongs to the drug class dopaminergic antiparkinsonism agents. Risk cannot be ruled out during pregnancy. Carbidopa/levodopa 25 mg / 250 mg is not a controlled substance under the Controlled Substance Act (CSA).

Carbidopa and levodopa (orally disintegrating)

Imprint:

M C53

Strength:

25 mg / 250 mg

Color:

Green

Shape:

Round

Availability:

Prescription only

Drug Class:

Dopaminergic antiparkinsonism agents

Pregnancy Category:

C - Risk cannot be ruled out

CSA Schedule:

Not a controlled drug

Manufacturer:

Mylan Pharmaceuticals Inc.

National Drug Code (NDC):

00378-5053

Inactive Ingredients:

aspartame
crospovidone
mannitol
microcrystalline cellulose
silicon dioxide
sodium stearyl fumarate
sorbitol
FD&C Blue No. 1
D&C Yellow No. 10

More info Print Imprint Search

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.